{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:08:03Z","timestamp":1794254883082,"version":"4.9.0"},"reference-count":119,"publisher":"American Chemical Society (ACS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chem. Res. Toxicol."],"published-print":{"date-parts":[[2024,2,19]]},"DOI":"10.1021\/acs.chemrestox.3c00327","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T22:32:43Z","timestamp":1707172363000},"page":"181-198","source":"Crossref","is-referenced-by-count":63,"title":["Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-2996","authenticated-orcid":true,"given":"David J.","family":"Snodin","sequence":"first","affiliation":[{"name":"Xiphora Biopharma Consulting, Bristol BS6 7BG, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Trejo-Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Nonclinical Safety and Pathobiology (NSP), Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6840-2629","authenticated-orcid":true,"given":"David J.","family":"Ponting","sequence":"additional","affiliation":[{"name":"Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0393-3650","authenticated-orcid":true,"given":"Graham F.","family":"Smith","sequence":"additional","affiliation":[{"name":"AstraZeneca, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, Research and Development, CB2 0AA Cambridge, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Czich","sequence":"additional","affiliation":[{"name":"Sanofi, Research and Development, Preclinical Safety, 65926 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cross","sequence":"additional","affiliation":[{"name":"Instem, Conshohocken, Pennsylvania 19428, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Custer","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Nonclinical Safety, New Brunswick, New Jersey 08903, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Elloway","sequence":"additional","affiliation":[{"name":"AstraZeneca, Safety Sciences, Clinical Pharmacology and Safety Sciences Research and Development, CB2 0AA Cambridge, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Greene","sequence":"additional","affiliation":[{"name":"AstraZeneca, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, Research and Development, Waltham, Massachusetts 02451, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-756X","authenticated-orcid":true,"given":"Amit S.","family":"Kalgutkar","sequence":"additional","affiliation":[{"name":"Medicine Design, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Stalford","sequence":"additional","affiliation":[{"name":"Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Tennant","sequence":"additional","affiliation":[{"name":"Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Vock","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim Pharma GmbH & Co., KG, 88397 Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-9565","authenticated-orcid":true,"given":"Adam","family":"Zalewski","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceuticals, Genetic and Computational Toxicology, 13342 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceuticals, Genetic and Computational Toxicology, 13342 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-1210","authenticated-orcid":true,"given":"Krista L.","family":"Dobo","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Global Portfolio and Regulatory Strategy, Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-6915(99)00024-1"},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2003.08.006"},{"key":"ref3\/cit3","unstructured":"International Council for Harmonization of Technical Requirements\nfor Pharmaceuticals for Human Use.  ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities\nin Pharmaceuticals to Limit Potential Carcinogenic Risk M7; U.S. FDA, 2023."},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105403"},{"key":"ref6\/cit6","volume-title":"Procedure Number: EMEA\/H\/A-5(3)\/1490","volume":"369136","author":"European Medicines Agency","year":"2020"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.028"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02120"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2020.000036"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2022.105247"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2022.02.005"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00199"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01498"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00008"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.1c00369"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00217"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2020.106539"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00380"},{"key":"ref20\/cit20","unstructured":"European Medicines Agency. Questions and answers for marketing authorisation holders\/applicants\non the CHMP Opion for the Article 5(3) of Regulation (EC) No 726\/2004\nreferral on nitrosamine impurities in human medicianl products.  EMA\/409815\/2020 Rev 16; U.S. FDA, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/updated-information-recommended-acceptable-intake-limits-nitrosamine-drug-substance-related."},{"key":"ref21\/cit21","unstructured":"Health Canada.  Guidance on\nnitrosamine impurities in medications. Evaluating and managing the\nrisks of N-nitrosamine impurities in human pharmaceutical, biological\nand radiopharmaceutical products; Health\nCanada, 2023. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/nitrosamine-impurities\/medications-guidance\/guidance-nitrosamine%20impurities-medications.pdf."},{"key":"ref22\/cit22","unstructured":"United States Food and Drug Administration.  Recommended Acceptable Intake Limits for\nNitrosamine Drug\nSubstance-Related Impurities (NDSRIs). Guidance for Industry; U.S. Department of Health and Human Services. Center\nfor Drug Evaluation and Reserach (CDER). Food and Drug Administration, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/updated-information-recommended-acceptable-intake-limits-nitrosamine-drug-substance-related."},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094559"},{"issue":"2","key":"ref24\/cit24","first-page":"241","volume":"8","author":"Archer M. C.","year":"1989","journal-title":"Cancer Surv"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1021\/tx00046a016"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1021\/tx980005y"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1021\/tx0502037"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1110(87)90026-1"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.84589"},{"key":"ref30\/cit30","unstructured":"United States Environmental Protection\nAgency.  Health effects regarding N-nitrosodimethylamine\n(NDMA); U.S. EPA, 2023. https:\/\/semspub.epa.gov\/work\/01\/483524.pdf."},{"key":"ref31\/cit31","first-page":"1892","author":"Dutton A. H.","year":"1956","journal-title":"J. Chem. Soc."},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1136\/oem.19.4.276"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1042\/bj0850072"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00524152"},{"issue":"4","key":"ref35\/cit35","first-page":"517","volume":"73","author":"Kohda K. H.","year":"1982","journal-title":"Gann"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/2.4.349"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90420-9"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/17.9.2029"},{"key":"ref39\/cit39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B0-08-045044-X\/00119-X","volume-title":"Comprehensive Medicinal Chemistry II","author":"Trager W. F.","year":"2007"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26071917"},{"key":"ref41\/cit41","volume-title":"RIVA-FLUOXETINE (FLUOXETINE hydrochloride) Capsules Antidepressent\/Antiobsessional\/Antibulimic","author":"Laboratoire Riva Inc","year":"2004"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2018.1555587"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(91)90017-C"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1021\/jp206570n"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/3.9.1039"},{"issue":"13","key":"ref46\/cit46","first-page":"3373","volume":"47","author":"Wade D.","year":"1987","journal-title":"Cancer Res."},{"issue":"2","key":"ref47\/cit47","first-page":"447","volume":"47","author":"Keefer L. K.","year":"1987","journal-title":"Cancer Res."},{"issue":"6","key":"ref48\/cit48","first-page":"1499","volume":"48","author":"Yoo J. S. H.","year":"1988","journal-title":"Cancer Res."},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/12.1.127"},{"key":"ref50\/cit50","first-page":"351","volume":"105","author":"Appel K. E.","year":"1991","journal-title":"Iarc Sci. Publ"},{"issue":"84","key":"ref51\/cit51","first-page":"117","author":"Appel K. E.","year":"1987","journal-title":"Iarc Sci. Publ"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2797(91)90007-T"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.5.559"},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1021\/tx960077u"},{"key":"ref55\/cit55","unstructured":"Environment Canada Health Canada. Priority Substances List Assessment\nReport N-Nitrosodimethylamine\n(NDMA). In  Canadian Environmental Protection\nAct, 1999; Environment Canada, 2001. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/ewh-semt\/alt_formats\/hecs-sesc\/pdf\/pubs\/contaminants\/psl2-lsp2\/nitrosodimethylamine\/ndma-eng.pdf."},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq121"},{"key":"ref57\/cit57","doi-asserted-by":"publisher","DOI":"10.1021\/tx0001979"},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1177\/0192623309356453"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(93)90118-Y"},{"key":"ref60\/cit60","volume-title":"Toxicological Profile for N-Nitrosodiphenylamine","author":"Agency for Toxic Substances and Disease Registry (ASTDR)","year":"2017"},{"key":"ref61\/cit61","unstructured":"European\nChemicals Agency (ECHA).  N-Nitrosodiphenylamine\nCAS Number 86\u201330\u20136; ECHA, 2018. https:\/\/echa.europa.eu\/it\/registration-dossier\/-\/registered-dossier\/27089\/1\/2."},{"key":"ref62\/cit62","unstructured":"Lhasa Limited Carcinogenicity Database.  Lhasa Carcinogenicity Database; Lhasa Limited, 2023. https:\/\/carcdb.lhasalimited.org\/."},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(97)89405-0"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1021\/tx00013a003"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(98)00369-3"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(82)90130-6"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1021\/tx00046a002"},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2797(96)03722-2"},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1016\/j.dyepig.2020.108726"},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.1042\/bj0910035"},{"key":"ref71\/cit71","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/3.2.155"},{"key":"ref72\/cit72","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/3.7.777"},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1155\/S1110724304402034"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.1.355"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(99)00020-1"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1124\/pr.120.019240"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020094"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2008.05.003"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2007.04.026"},{"key":"ref80\/cit80","unstructured":"United States Environmental Protection Agency.  Integrated Risk Information System (IRIS) Chemical Assessment\nSummary. Nitric Oxide; CASRN 10102\u201343\u20139; National Center for Environmental Assessment. U.S. Environmental\nProtection Agency, 1994. https:\/\/iris.epa.gov\/static\/pdfs\/0077_summary.pdf."},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.1016\/0165-7992(92)90008-6"},{"key":"ref82\/cit82","unstructured":"ECHA.  Nitrogen\nMonoxide CAS\nNumber 10102\u201343\u20139; ECHA, 2018. https:\/\/echa.europa.eu\/registration-dossier\/-\/registered-dossier\/24163\/1\/2."},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2017.4786"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1016\/0013-9351(80)90137-1"},{"key":"ref85\/cit85","unstructured":"Australian Government.  Australian Public Assessment\nReport for Nitric Oxide. Proprietary Product Name: VasoKINOX. Sponsor:\nAir Liquide Healthcare Pty Ltd. Administration, Department of Health\nTherapeutic Goods Administration; Australian\nGovernment, 2018. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-nitric-oxide-180115.pdf."},{"key":"ref86\/cit86","doi-asserted-by":"publisher","DOI":"10.1161\/hh0102.102330"},{"key":"ref87\/cit87","unstructured":"United States Environmental Protection Agency.  Provisional Peer Reviewed Toxicity Values for Nitroglycerin\n(CASRN 55\u201363\u20130) Derivation of Subchronic and Chronic\nOral RfDs. Superfund Health Risk Technical Support Center; National Center for Environmental Assessment, U.S.\nEnvironmental Protection Agency, 2006. https:\/\/cfpub.epa.gov\/ncea\/pprtv\/documents\/Nitroglycerin.pdf."},{"key":"ref88\/cit88","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/17.11.2477"},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/4.2part1.248"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104926"},{"issue":"57","key":"ref91\/cit91","first-page":"627","author":"Peto R.","year":"1984","journal-title":"Iarc Sci. Publ"},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.3.499"},{"issue":"4","key":"ref93\/cit93","first-page":"681","volume":"68","author":"Lijinsky W.","year":"1982","journal-title":"J. Natl. Cancer Inst"},{"issue":"1","key":"ref94\/cit94","first-page":"19","volume":"40","author":"Lijinsky W.","year":"1980","journal-title":"Cancer Res."},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1021\/bk-1981-0174.ch004"},{"issue":"6","key":"ref96\/cit96","first-page":"1988","volume":"36","author":"Lijinsky W.","year":"1976","journal-title":"Cancer Res."},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(95)04078-1"},{"key":"ref98\/cit98","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105415"},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910160215"},{"key":"ref100\/cit100","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/55.3.705"},{"key":"ref101\/cit101","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/8.9.1337"},{"issue":"4","key":"ref102\/cit102","first-page":"1288","volume":"41","author":"Lijinsky W.","year":"1981","journal-title":"Cancer Res."},{"issue":"5","key":"ref103\/cit103","first-page":"771","volume":"67","author":"Okada M.","year":"1976","journal-title":"Gan"},{"key":"ref104\/cit104","unstructured":"Carlson, E. K. Metabolic activation and DNA-damaging properties of carcinogenic N-nitrosamines; University of Minnesota, 2019. https:\/\/core.ac.uk\/download\/pdf\/226939699.pdf."},{"key":"ref105\/cit105","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(89)90106-3"},{"key":"ref106\/cit106","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2008.06.082"},{"key":"ref107\/cit107","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2019.5568"},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1021\/tx5001046"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.1021\/ed077p1644"},{"key":"ref110\/cit110","unstructured":"United States\nEnvironmental Protection Agency.  Guidelines\nfor Cancer Risk Assessment; US EPA, 2005. http:\/\/www.epa.gov\/cancerguidelines\/."},{"key":"ref111\/cit111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054684"},{"key":"ref112\/cit112","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(81)90239-1"},{"key":"ref113\/cit113","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770010306"},{"key":"ref114\/cit114","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(78)90228-2"},{"key":"ref115\/cit115","doi-asserted-by":"publisher","DOI":"10.1002\/em.2860050703"},{"key":"ref116\/cit116","doi-asserted-by":"publisher","DOI":"10.1002\/em.2850110602"},{"key":"ref117\/cit117","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2005.02.004"},{"key":"ref118\/cit118","doi-asserted-by":"publisher","DOI":"10.1002\/em.2860060702"},{"key":"ref119\/cit119","unstructured":"National Toxicology Program.  Testing Status of N-Nitrosodipehnylamine\n10423-H; National Toxicology Program, 2023. https:\/\/ntp.niehs.nih.gov\/static\/whatwestudy\/testpgm\/status\/ts-10423-h.html (accessed 08-16-2023)."}],"container-title":["Chemical Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.chemrestox.3c00327","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.chemrestox.3c00327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T09:10:54Z","timestamp":1708333854000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.chemrestox.3c00327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,19]]}},"alternative-id":["10.1021\/acs.chemrestox.3c00327"],"URL":"https:\/\/doi.org\/10.1021\/acs.chemrestox.3c00327","relation":{},"ISSN":["0893-228X","1520-5010"],"issn-type":[{"value":"0893-228X","type":"print"},{"value":"1520-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}